Search Results
Jun 23, 2026, 09:00 ET NorthLinks Bio Launches with $34 Million Financing to Advance Broad-Spectrum Respiratory Antiviral Platform
glycan-targeted platform for prevention and treatment of respiratory viral infections. Proceeds will also support HEX17 manufacturing and establish NorthLinks Bio's US operations to support future clinical development in influenza and other respiratory viral indications.HEX17 is a convenient intranasal spray
More news about: Northlinks Bio
Jun 23, 2026, 09:00 ET Sharp Unveils New High-Speed Color Office Series Featuring Enhanced Productivity and Performance
technology is built into the new BP High-Speed Color Office Series to help organizations better protect sensitive business information. Key features include BIOS integrity checks at startup, real-time intrusion detection, and available anti-malware protection powered by Bitdefender® to help safeguard
More news about: Sharp Imaging and Information Company of America (SIICA)
Jun 23, 2026, 08:47 ET Mercury Bio Promotes Casey Perkins to Chief Business Officer
preclinical programs. Her promotion to Chief Business Officer reflects the scope of her work and recognizes her role on the leadership team as Mercury Bio's technologies advance toward the clinic.Perkins, recently recognized by
More news about: Mercury Bio Inc.
Jun 23, 2026, 08:00 ET Rapalogix Health Raises $20 Million in Series A Financing to Redefine the Future of Longevity-Based Skin Health
line, Re-Q, is based on the company's proprietary approach to selectively modulating TORC1 activity in skin cells. This approach builds on Cambrian Bio's TORnado platform, which solved a longstanding challenge in achieving selective TORC1 modulation, and Rapalogix was spun out to apply this breakthrough
More news about: Rapalogix Health, Inc.
Jun 22, 2026, 11:39 ET CJ BIO to Showcase TasteNrich® Taste Lab for Sodium Reduction, Clean Label, and Taste Design Solutions at IFT FIRST 2026
expect?CJ BIO's approach is taste design. Instead of focusing only on reduction, CJ BIO helps developers build more balanced taste systems by optimizing salt perception, umami, mouthfeel, masking, flavor balance, and savory impact.What Is TasteNrich®?TasteNrich® is CJ BIO's natural
More news about: CJ BIO
Jun 22, 2026, 10:31 ET Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveInsight
both physical and neurocognitive disease manifestations while potentially overcoming the challenges associated with allogeneic HSCT.Orca Bio's Orca-T is an investigational allogeneic T-cell immunotherapy being studied for the treatment of various hematologic malignancies, including acute
More news about: DelveInsight Business Research, LLP
Jun 19, 2026, 11:00 ET Seoul National University Hospital to Expand Global K-Bio Collaboration at BIO USA 2026
June 19, 2026 /PRNewswire/ -- Seoul National University Hospital (SNUH) will take a major step toward expanding K-Bio's global presence and international collaboration at BIO International Convention 2026 (BIO USA), the world's largest biotechnology industry event. Through
More news about: Seoul National University Hospital (SNUH)
Jun 18, 2026, 11:29 ET Deck Bio to Present Multi-pMHC T Cell Engager Platform at the 8th T-Cell Engager Therapeutics Summit and BIO 2026
pMHCs, DBXO-1 is designed to expand patient eligibility and improve durability of response across major solid tumor indications.Details of Deck Bio's participation are as follows:8th T-Cell Engager Therapeutics SummitDate: June 23-25, 2026Location:
More news about: Deck Bio, Inc.
Jun 18, 2026, 08:00 ET Matica Biotechnology Launches Integrated Korea IIT Platform Solution to Accelerate Global Advanced Therapy Development
collaboration with Korea's top clinical and hospital network, the integrated platform combines globally recognized Korean clinical execution with Matica Bio's U.S. based manufacturing, process development, analytical development, and translational CMC expertise.The launch comes at a pivotal time for
More news about: Matica Biotechnology, Inc.
Jun 18, 2026, 07:00 ET Transpire Bio to Present at the 2026 BIO International Convention
Mr. Clifton's presentation is scheduled for Wednesday, June 24, 2026, at 3:00 PM in Theater 1.During the event, Transpire Bio's leadership team will be actively connecting with global biotech innovators and potential strategic partners. The company is seeking to leverage its
More news about: Transpire Bio
Jun 18, 2026, 06:55 ET IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization
where we submitted an international NDA and received approval, marking a critical milestone in IASO Bio's 'go global' strategy. This approval serves as a powerful international validation of IASO Bio's CAR-T product quality system, manufacturing capabilities, and global cold-chain logistics reach. It
More news about: IASO Bio
Jun 16, 2026, 08:43 ET TriasMD Unveils New Executive Leadership Team to Lead its Next Chapter of Growth
leadership team members Michael Bailey (VP of Development), Beverly Kirchner (VP of Compliance) and Catherine Ruppe (VP of ASC Operations). Read all of their bios
More news about: TriasMD
Jun 16, 2026, 08:15 ET Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing" (June 15, 2026; primary source for the board expansion, appointee bios, committee assignments, CXU™/Ten-Minute Tissue™ platform, and CEO Miles Harrison quote):
More news about: American News Group
Jun 16, 2026, 08:05 ET When Stitches Act Like Saws: Florida Surgeons Publish New Strategy for Severe Muscle Injuries
involved in complex trauma and wound reconstruction.Peter Gonzalez, MD is Chief of Trauma at Delray Medical Center.Surgeon bios:
More news about: Plastic Surgery Trauma Associates
Jun 16, 2026, 08:00 ET Matica Biotechnology and Cirsium Biosciences Announce Adoption of Matica Open Access Platform to Accelerate Flexible AAV Manufacturing
manufacturing. This milestone builds on the companies' existing collaboration, integrating Cirsium's plant-based AAV technology with Matica Bio's downstream and analytical expertise to improve efficiency and scalability in gene therapy manufacturing.Unlike traditional CDMO engagement models
More news about: Matica Biotechnology, Inc.
Jun 16, 2026, 06:07 ET EndoDNA Launches BIOS, Turning Genetic Data Into Living Clinical Intelligence for Precision Medicine
cognitive functionIn all, BIOS analyzes approximately 1 million validated variants across 21 pathway systems, with 214 pathways actively curated for real-time clinical decision support.How BIOS works: four connected memory networksBIOS doesn't read a single data point in isolation.
More news about: EndoDNA
Jun 15, 2026, 14:11 ET Hillhurst Bio Doses First Subject in Phase 2a Clinical Trial of HBI-002, a Novel Therapy for Parkinson's Disease
disease. Parkinson's disease affects approximately 1.1 million people in the United States.About HBI-002:HBI-002 is Hillhurst Bio's lead investigational product candidate, an oral low-dose carbon monoxide (CO) drug designed for chronic use in a home setting by patients with Parkinson's
More news about: Hillhurst Biopharmaceuticals, Inc.
Jun 15, 2026, 06:00 ET Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®
More news about: Halozyme Therapeutics, Inc.
Jun 11, 2026, 10:07 ET Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
VCapital, with participation from Merck Animal Health, Connecticut Innovations, and Digitalis. Proceeds will support continued advancement of Rejuvenate Bio's gene therapy platform and pipeline, including treatments designed to address chronic and age-associated diseases in companion animals.Alongside
More news about: LifeSpan Vision Ventures
Jun 11, 2026, 09:59 ET Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
VCapital, with participation from Merck Animal Health, Connecticut Innovations, and Digitalis. Proceeds will support continued advancement of Rejuvenate Bio's gene therapy platform and pipeline, including treatments designed to address chronic and age-associated diseases in companion animals.Alongside
More news about: LifeSpan Vision Ventures
Jun 11, 2026, 09:10 ET Aspen Neuroscience Appoints Jeff Boerneke as General Counsel and Secretary
governance, public company reporting, financings, licensing and partnerships, intellectual property, and clinical and commercial contracting. He led Gossamer Bio's 2019 initial public offering and most recently its global partnership with Chiesi.Prior to Gossamer Bio, Mr. Boerneke served as Corporate Counsel
More news about: Aspen Neuroscience, Inc.
Jun 11, 2026, 08:28 ET Immorta Bio Publishes Over 70% Increased Longevity in Aging Animals by its Patented Therapeutic Combination
https://link.springer.com/article/10.1186/s12967-026-08221-ySenoVax™ is Immorta Bio's first-in-class senolytic immunotherapy platform. StemCellRevivify™ is Immorta Bio's regenerative platform focused on restoring youthful biology through personalized cellular rejuvenation technologies.
More news about: Immorta Bio Inc.
Jun 11, 2026, 07:45 ET Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
advanced state of readiness and response to radiation and nuclear exposures.The development closely follows [comes on the heels of] Valion Bio's
More news about: Valion Bio, Inc.
Jun 10, 2026, 23:18 ET GIGABYTE mejora el rendimiento de sus placas base con tecnologías impulsadas por IA
base para mejorar la integridad de la señal y mantener un rendimiento óptimo en diseños de placas base multicapa. Además, HyperTune BIOS, la tecnología de optimización de BIOS basada en IA de GIGABYTE, ajusta de forma inteligente el comportamiento de la memoria para lograr una velocidad de reloj de memoria
More news about: GIGABYTE
Jun 10, 2026, 11:14 ET TOUGHBOOK GUARD SETS NEW STANDARDS FOR HARDWARE-BASED ENDPOINT SECURITY
the BIOS to deliver enterprise-grade protection throughout the entire device lifecycle. As cybersecurity risks increase, additional security layers from hardware vendors are now essential. TOUGHBOOK Guard uses a secure-by-design approach, embedding hardware-level protection directly into the BIOS at the
More news about: Panasonic Connect Europe